Objectives To demonstrate the feasibility of MRI-based assessment of the intrahepatic Ho-PLLA-MS biodistribution after radioembolisation in order to estimate the absorbed radiation dose. Methods Fifteen patients were treated with holmium-166 ( 166 Ho) poly(L-lactic acid)-loaded microspheres (Ho-PLLA-MS, mean 484 mg; range 408-593 mg) in a phase I study. Multi-echo gradient-echo MR images were acquired from which R 2 * maps were constructed. The amount of Ho-PLLA-MS in the liver was determined by using the relaxivity r 2 * of the Ho-PLLA-MS and compared with the administered amount. Quantitative single photon emission computed tomography (SPECT) was used for comparison with MRI regarding the whole liver absorbed radiation dose. Results R 2 * maps visualised the deposition of Ho-PLLA-MS with great detail. The mean total amount of Ho-PLLA-MS detected in the liver based on MRI was 431 mg (range 236-666 mg) or 89±19 % of the delivered amount (correlation coefficient r00.7; P<0.01). A good correlation was found between the whole liver mean absorbed radiation dose as assessed by MRI and SPECT (correlation coefficient r00.927; P<0.001). Conclusion MRI-based dosimetry for holmium-166 radioembolisation is feasible. Biodistribution is visualised with great detail and quantitative measurements are possible. Key Points • Radioembolisation is increasingly used for treating unresectable primary or metastatic liver tumours.
Introduction
Yttrium-90 ( 90 Y) radioembolisation (RE) is increasingly used for the treatment of patients with unresectable primary or metastatic liver tumours [1] [2] [3] [4] [5] [6] . The two commercially available products, SIR-Spheres® (Sirtex Medical Limited, North Sydney, NSW, Australia) and TheraSphere® (Nordion, Ottawa, Canada), use empirical methods for dose calculation, based on body surface area and total liver weight respectively. However, apart from the total dose delivered to the liver, the efficacy of RE will largely depend on the intrahepatic dose distribution or, more specifically, on the ratio between the tumour absorbed dose and healthy tissue absorbed dose.
Quantitative assessment of the post-administration intrahepatic microsphere distribution is therefore indispensable for evaluation of RE toxicity and efficacy and can potentially be used for the prediction of patient response and patient-specific therapeutic dose optimisation. Image-based approaches to assess microsphere distribution after RE have gained interest but are mostly hampered by the limited imaging possibilities of the isotope 90 Y. Quantitative 90 Y-SPECT imaging has limited spatial resolution because it is based on 90 Y Bremsstrahlung [7] [8] [9] [10] , whereas 90 Y-PET has better spatial resolution but low sensitivity [11, 12] . As a consequence, alternative methods of visualising the microspheres have been investigated, such as MR imaging of iron-labelled microspheres [13] .
In the past decade, holmium-166 ( 166 Ho) poly(L-lactic acid)-loaded microspheres (Ho-PLLA-MS) have been developed as a potential radioembolisation particle [14, 15] . Neutron activated holmium-166 is a β-emitting (E max 01.77 and 1.854 MeV; I β 048.7 % and 50 %, respectively; T 1/2 0 26.83 h) and γ-emitting (E γ 080.6 keV) lanthanide that, embedded in microspheres of poly(L-lactic acid), yields a particle suitable for internal radiation therapy that can be visualised with a range of clinical imaging techniques, including SPECT and MRI. This multimodal imaging has previously been demonstrated in preclinical animal studies [16] [17] [18] . It was also shown that MRI combines high sensitivity with high spatialtemporal resolution and with superior soft tissue contrast [19] and thus can be used to cover a broad range of clinically interesting imaging parameters. More recently, it was shown for an ex vivo situation that MRI is able to provide a good measurement of the Ho-PLLA-MS radiation-absorbed dose by convolution of quantitative MRI data with a 166 Ho dose point kernel [20] .
The feasibility of image-guided RE using Ho-PLLA-MS was tested in a first-time-in-man clinical phase I study. The aim of the work described in this article was to investigate the capability of MRI to measure the intrahepatic microsphere distribution in order to quantify the absorbed radiation dose in patients treated with Ho-PLLA-MS radioembolisation.
Materials and methods

Patients
To be eligible to enter the phase I study each patient needed to comply with the following inclusion criteria: written informed consent; age 18 years or older; presence of liverdominant, unresectable, chemorefractory liver metastases of any primary tumour with at least one measurable lesion of ≥10 mm in the longest diameter on CT; an estimated life expectancy >3 months; World Health Organisation (WHO) performance status 0-2; and a negative pregnancy test for women. Furthermore, patients with contraindications for MRI were excluded from treatment. Ethics approval for this study was obtained from the institutional review board; the study was performed in accordance with the Declaration of Helsinki and was registered with Clinicaltrials.gov, no. NCT01031784.
Treatment
Holmium-165 poly(L-lactic acid) microspheres with a mean diameter of 30 μm (range 20-50 μm) and a holmium content of 18.7 % (weight/weight) were prepared under Good Laboratory Practice (GLP) guidelines as previously described [14] . The amount of microspheres (600 mg) was weighed, packed in high-density polyethylene vials (Posthumus Plastics, Beverwijk, The Netherlands) and sent to the nuclear reactor (Delft University of Technology, Delft, The Netherlands) for neutron activation [21] . The calculation of the amount of radioactivity was based on liver weight, conforming to the clinically used approach for TheraSphere®. The amount of administered 166 Ho-radioactivity was calculated using the target liver absorbed dose in a dose-escalation fashion (20, 40, 60 , or 80 Gy) as previously described [22] . All patients received whole liver treatment. The activity to be administered was calculated assuming homogeneous distribution of the activity in the liver using the following formula: A Ho166 (MBq)0Liver Dose × 63 (MBq/J) × LW where A Ho166 is the administered activity, LW is the liver weight in kg, and Liver Dose is the intended liver absorbed radiation dose in Gy. While the radioactivity was different for each patient, the amount of administered Ho-PLLA-MS was kept constant at 600 mg. Before administration, the amount of radioactivity in the vials was measured using a dose calibrator (VDC-404, Veenstra Instrumenten B.V., Joure, The Netherlands), and the specific activity of the Ho-PLLA-MS was determined. After administration, activity measurements were performed on the administration system to determine the amount of microspheres that was actually delivered to the subjects retrospectively.
Radioembolisation procedures
Radioembolisation was performed according to standard recommendations [23, 24] . Relevant vessels in particular branches of the hepatic artery supplying organs other than the liver, e.g., the gastroduodenal artery (GDA) and right gastric artery (RGA), were coiled during a pre-treatment angiographic procedure to prevent extrahepatic deposition of activity. A scout dose of Tc-MAA (150 MBq, 0.8 mg, TechneScan LyoMaa®, Mallinckrodt Medical B.V., Petten, The Netherlands) was injected into the hepatic artery followed by planar gamma camera imaging and SPECT to check for inadvertent extrahepatic deposition. The 99m Tc-MAA lung shunt was measured by planar scintigraphic imaging, and shunt fractions were determined by region of interest (ROI) analyses [25] . If the lung shunt fraction of 99m Tc-MAA was <20 % and no other extrahepatic deposition of 99m Tc-MAA was detected, treatment with Ho-PLLA-MS was performed within 2 weeks.
Data acquisition for dosimetry
For intrahepatic biodistribution assessment of the microspheres, abdominal SPECT and MRI were performed.
MRI
Magnetic resonance images were acquired 1-2 weeks before and 1 week after administration of the therapeutic dose of Ho-PLLA-MS. Since MRI utilises the paramagnetic nature of the microspheres rather than the radioactivity, the post-therapy imaging time point was of minor relevance, and post-therapy images were acquired during the patients' first weekly visit at the outpatient clinic after treatment. Imaging was performed using a 1.5-T whole body system (Achieva, Philips Healthcare, Best, The Netherlands) equipped with a 16-element torso coil. For detection and quantification of Ho-PLLA-MS, a multi-slice multi-gradient echo (MGE) sequence was used, acquiring 16 echoes during breath hold with an in-plane resolution of 2×2 mm 2 and a slice thickness of 6 mm. Imaging parameters included: FOV: 288×384 mm 2 , number of slices: 45, TR/TE1/ΔTE: 440 ms/ 1.33 ms/1.15 ms, flip angle: 50°. Sensitivity encoding (SENSE) with a factor of 2.5 was used for acceleration resulting in an imaging time of 3×19 s during breath hold. For anatomical information and segmentation purposes, T 2 -weighted turbo spin echo (TSE) images were acquired with identical FOV and voxel size. Imaging parameters included: TR/TE: 830 ms/80 ms; SENSE factor: 2; imaging time: 2× 19 s during breath hold. In addition, T 1 -weighted turbo field echo (TFE) images were acquired using an in-plane resolution of 1.8×3.6 mm 2 ; slice thickness: 10 mm; TR/TE: 8.5 ms/ 4.18 ms; total imaging time: 2×14 s during breath hold.
To determine the sensitivity of MRI for Ho-PLLA-MS, as expressed by the r 2 * relaxivity (relaxation rate per mg/ml Ho-PLLA-MS), a calibration phantom setup containing known microsphere concentrations (0, 2.1, 4.1, 6.1 and 8 mg/ml Ho-PLLA-MS in agarose gel) was imaged using the MGE sequence described above.
SPECT
Single photon emission computed tomography images were acquired 3-6 days after administration of Ho-PLLA-MS. The imaging time point did depend on the total activity that was administered to the patient and was based on the maximum tolerated count rate of the SPECT system to acquire images without dead-time effects. The first nine patients underwent imaging using a FORTE TM dual-headed gamma camera (FORTE TM , Philips Medical Systems, Milpitas, CA, USA) equipped with gadolinium-153 scanning line sources for transmission CT. The last six patients underwent imaging using a Siemens Symbia T16 SPECT/CT system (Siemens, Erlangen, Germany), which combines a dual-headed gamma camera with a 16-slice CT system. Medium energy collimators were used on both systems. Energy windows were set at 80.6 keV (15 % window width) for the holmium-166 photo peak and at 118 keV (12 % (Symbia T16), using an ordered subsets expectation maximisation algorithm including a hybrid scatter correction method [26] , resulting in an absolute quantitative 3D activity distribution in MBq/voxel.
Data analyses
Magnetic resonance images were processed using software code written in MATLAB (MathWorks, Natick, MA, USA).
From the MGE MRI patient data, R 2 * values were estimated voxelwise using a mono-exponential fitting algorithm weighting all signal amplitudes equally. To minimise the influence of noise, signal intensities lower than 3σ were excluded from the fitting procedure, with σ the standard deviation (SD) of the signal determined in a region with homogeneous signal intensity and free from Ho-PLLA-MS. R 2 * values were determined for data obtained both before and after RE. For further analysis, the liver was manually segmented based on the tissue contrast of the corresponding T 2 -weighted TSE images. The distribution of estimated liver R 2 * values was measured, and the mean R 2 * value together with the SD was calculated.
To determine the change in R 2 * (ΔR 2 * ) after therapy, a baseline R 2 * value determined by the mean R 2 * of the liver before Ho-PLLA-MS administration was subtracted from the post-therapy R 2 * maps. Voxelwise concentrations of Ho-PLLA-MS were determined from the ΔR 2 * maps by the relationship [Ho-PLLA-MS]0ΔR 2 * /r 2 * , with r 2 * measured from the calibration phantom setup. Using the voxel volume and the total volume included in the segmentation, the total amount of Ho-PLLA-MS in the liver was determined. For all patients, the MRI-based amount was compared with the total amount that was assumed to be delivered to the liver. This amount was determined by correcting the delivered amount of Ho-PLLA-MS by the 99m Tc-MAA lung shunt fraction and the amount of Ho-PLLA-MS left in the administration system. Data from patients who had surgical clips implanted (as a consequence of former partial liver resection) were separated from the patients without clips, and means were also compared separately for these two groups. This separation was made because metallic surgical clips are known to distort gradient echo images [27] [28] [29] and hence were suspected to influence MRI-based quantification.
As a final step, the mean radiation absorbed dose was calculated on a whole liver level using MRI and SPECT dose maps that were constructed using the method previously described for an ex-vivo liver model [20] . In short, MRI concentration values were converted into MBq/voxel using the voxel size and the specific activity of the microspheres (MBq/mg) at the moment of injection. [31] . The voxel size of the dose point kernel was equal to the native resolution of the image technique (2×2×6 mm for MRI, 4.7 mm isotropic for SPECT). After manual co-registration of SPECT maps to MRI and segmentation, mean liver absorbed dose values were calculated for both techniques.
Statistical analysis
Descriptive statistics of means, standard deviations and ranges were calculated for continuous variables. The paired Student's t-test was used for comparison of means (two-tailed 95 % confidence interval). Bivariate Pearson's correlation (one-tailed 95 % confidence interval) was used for correlation between Ho-PLLA-MS calculations based on MRI and the actual amount for the whole liver and the correlation between MRI and SPECT dosimetry on a whole liver level. SPSS software (SPSS for Windows, version 13.0; SPSS Inc., Chicago, IL, USA) was used for all analyses.
Results
Fifteen patients were included in this phase I dose-escalation study. Nine men and six women, median age 55 years (range 38-87 years), were treated with escalating whole liver doses of 20-80 Gy. The median number of liver tumours was 5 (range 1-21), with a median fractional liver involvement of 14 % (range 2-52 %), originating from an ocular melanoma (7 patients), colorectal carcinoma (5 patients), cholangiocarcinoma (2 patients) or breast carcinoma (1 patient). Five patients had surgical clips implanted in the liver as a consequence of former partial liver resection (number of clips ranging from 1 to >20). MRI data were analysed for 14 patients. One patient was excluded from MRI analysis because of incomplete data. The patients received a mean of 523 mg Ho-PLLA-MS (range 438-640 mg). Corrected for shunting to the lungs (mean 7.4 %; range 3.0-13.0 %), the mean administered amount of Ho-PLLA-MS to the liver was 484 mg (range 408-593 mg; Table 1 ).
Ho-PLLA-MS caused enhanced MR signal decay after administration, translating into high R 2 * values (Fig. 1) . Strongly increased R 2 * values were observed locally, corresponding to tumour lesions with high signal intensity on T 2 -weighted images. Histograms of the R 2 * values found in the liver showed an overall shift of R 2 * values toward higher values and a broadening of the R 2 * distribution after treatment (Fig. 2) [19, 20] . This value was subsequently used to calculate Ho-PLLA-MS concentration maps. The concentration maps were comparable to the R 2 * maps with relatively high concentrations found at tumour sites (Fig. 3) . From the concentration maps and the volume of the liver, the amount of Ho-PLLA-MS was calculated. The mean total amount of Ho-PLLA-MS that was detected in the liver based on MRI was 431 mg (range 236-666 mg). For all patients this was 89±19 % (mean±SD) of the amount delivered to the liver (correlation coefficient r00.7; P<0.01). By excluding the data of the patients with surgical clips implanted in the liver, the mean MRI-based detected fraction increased to 96±13 % (mean±SD; correlation coefficient r 00.8; P < 0.01; Table 1 ). MRI showed that the presence of surgical clips in the liver led to undetermined areas (black spots) surrounded by (virtual) high concentration values (Fig. 4) . This led to a poor correlation between Ho-PLLA-MS amounts calculated on MRI and the actual delivered amount of Ho-PLLA-MS (correlation coefficient r00.3; P00.29).
A good correlation was found between the whole liver mean absorbed radiation dose as assessed by MRI and SPECT (correlation coefficient r00.93; P<0.001 including all patients, correlation coefficient r00.98; P<0.001 excluding patients with surgical clips, correlation coefficient r00.81; P00.10 for only patients with clips). Magnetic resonance imaging displayed the local microsphere distribution in much more detail because of the relatively high in-plane resolution, for example revealing an absence of Ho-PLLA-MS in the central part of a furthermore highly targeted tumour in some cases. This situation was rather obscured in the corresponding SPECT images owing to the lower resolution and blurring effects (Fig. 5) .
Discussion
In this article we presented the first in vivo quantitative MRI data of 166 Ho-poly(L-lactic acid) microspheres for imageguided radioembolisation using MRI.
Three-dimensional MRI-based assessment of the intrahepatic biodistribution of Ho-PLLA-MS was feasible. Ho-PLLA-MS concentration maps, which were constructed by using a time series of T 2 * -weighted images, clearly showed the ability of MRI to visualise the intrahepatic biodistribution of the microspheres. Furthermore, MRI provided both a quantitative measure of the Ho-PLLA-MS distribution and anatomical information, enabling direct localisation of the microsphere deposition within the tissue. MRI detected 89 % of the actual delivered Ho-PLLA-MS in the whole liver. The mean whole liver absorbed radiation dose calculated on MRI correlated very well with the absorbed radiation dose on SPECT. A more detailed intra-tumour biodistribution assessment was possible using MRI compared with SPECT because of the better spatial resolution of MRI. The quantitative nature of MRI-based biodistribution assessment of Ho-PLLA-MS allows for personalised dosimetry in vivo and may ultimately lead to optimisation of radioembolisation with regard to safety and efficacy. Tc-MAA-based lung shunt fraction, the MRI quantification method presented in this work showed on average an underestimation. As shown, this was in part due to the presence of surgical clips (Fig. 4) . These clips induced field distortions, resulting in large MR signal voids surrounded by large R 2 * values. Therefore, locally the amount of Ho-PLLA-MS cannot be determined resulting in an underestimation of the microsphere amount in the vicinity of the clips. Although the presence of surgical clips does not necessarily lead to a contraindication for MRI-based dosimetry, biodistribution measurements in the vicinity of the clips should be interpreted with care. Another source of the discrepancy between the MRI-based amount and the amount delivered may be the use of 99m Tc MAA as a predictor of the lung shunt fraction. Although used to correct for extrahepatic deposition in order to estimate the Ho-PLLA-MS liver amount, it is known that, because of a number of dissimilarities between 99m Tc MAA and Ho-PLLA-MS such as size, shape and density, 99m Tc MAA is not the optimal microsphere analogy [6] . Incorrect assessment of the lung shunt fraction may have led to an erroneous estimation of the amount of Ho-PLLA-MS delivered in the liver. This explanation is supported by the good correlation that was found between the MRI-based mean liver absorbed dose and the absorbed dose based on the more conventional method of image-based dosimetry, SPECT.
Quantification errors may also arise from the need to correct for baseline R 2 * values in order to determine ΔR 2 * . ΔR 2 * values were calculated by subtracting the mean liver R 2 * value before administration from the post-treatment R 2 * maps. Because of the variance of R 2 * in the absence of microspheres as a result of tissue characteristics (Fig. 1) , over-or underestimations will be introduced at the voxel level. The bias introduced in ΔR 2 * will depend on the local voxel R 2 * value with respect to the mean R 2 * over the whole VOI. In addition to these variations over space, changes may occur in tissue T 2 in the time interval between preand post-therapy imaging. Such changes may occur, for example, because of short-term therapy-induced oedema [32] , which leads to increasing T 2 values, and thus decreasing R 2 values, owing to the higher water content as is generally reflected by hyperintense areas on T 2 -weighted images [33] . A decrease in tissue R 2 may therefore counteract the increase in R 2 * because of Ho-PLLA-MS leading to an underestimation of Ho-PLLA-MS concentration.
To minimise these quantification errors, voxel-based subtraction of post-and pre-therapy maps seems to be crucial. Manual or (semi-) automatic registration of these maps may partly solve the problem, but a more robust solution will be to integrate MR imaging as part of the RE procedure. Data needed to construct the concentration maps shown in this work were acquired within 1 min, and data processing can be performed within several minutes. Considering this short time scale, it is feasible to perform personalised MRI-based dosimetry during the actual RE procedure. This would enable fast verification and give the opportunity, if necessary, to immediately adjust the RE procedure. Moreover, MRI would enable monitoring of the administration of the Ho-PLLA-MS in real time. This has previously been demonstrated in a pig model [34] . The first MRI data of patients treated with 166 Ho-poly (L-lactic acid) microspheres show the feasibility of MRIbased dosimetry for radioembolisation. Intrahepatic microsphere biodistribution can be visualised with great detail, and a good quantitative measurement of the absorbed radiation dose can be obtained within several minutes of the radioembolisation procedure. Biodistribution assessment in the vicinity of surgical clips should be interpreted with care.
